Managing the PCOS-Related Symptoms of Hirsutism, Acne, and Female Pattern Hair Loss

Shah, Trisha; Lieman, Harry

doi:10.1007/978-3-030-92589-5_11

Cited by 3 publications

(3 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Common signs of hyperandrogenism associated with PCOS include hirsutism, acne, and female pattern hair loss. The first-line treatment for hyperandrogenism symptoms is still combined hormonal contraceptives [ 9 ]. For hirsutism to improve, therapy must be administered for a minimum of six to nine months in women with moderate to severe hirsutism, or sudden onset rapidly progressing, or coupled with other abnormalities, such as menstrual dysfunction, obesity, or macroclitoris.…”

Section: Discussionmentioning

confidence: 99%

Impact of Laser Therapy on the Quality of Life in Women Living With Polycystic Ovary Syndrome-Associated Hirsutism: An Observational Study

Sakina,

Behram,

Jadoon

et al. 2024

Cureus

View full text Add to dashboard Cite

Introduction: This study aimed to observe the impact of laser-assisted hair removal (LAHR) on the quality of life in women with polycystic ovary syndrome (PCOS)-associated hirsutism. Methodology: An observational study was conducted on 172 women living with PCOS at a specialized clinic. The Dermatology Life Quality Index (DLQI) and Ferriman-Gallwey (FG) score were employed to assess the quality of life and severity of hirsutism, respectively. Laser therapy was administered using ruby diode or alexandrite lasers. Follow-up on the DLQI and FG score assessment was done at 12-, 18-, and 24-week post-treatment. Results: The number of cases that reported stress, anxiety, and depression reduced over time. However, there was no correlation between the patient-reported decrease and DLQI scores. The FG score was significantly related to mental health. The severity of the hirsutism impacted mental health. The regrowth of hair at six months indicated limited long-term efficacy LAHR. Conclusion: LAHR significantly improves the quality of life in the short term for women living with PCOS. However, the short-term benefit of the therapy indicates a need for research to find new treatment strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Laser Therapy on the Quality of Life in Women Living With Polycystic Ovary Syndrome-Associated Hirsutism: An Observational Study

Sakina,

Behram,

Jadoon

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Innumerable studies favor considering OCPs as conventional treatment in PCOS women indicating that OCP administration causes a decrease in free androgens, resulting in decreased new hair development and the growth of terminal hair [ 40 ]. OCPs are also responsible for diminishing inflammatory acne count by 30–60%, with 50–90% of patients improving [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women

Yousuf

Ganie

Urwat³

et al. 2023

BMC Women's Health

View full text Add to dashboard Cite

Background Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored. Method The relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software. Result Six months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002). Conclusion OCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities.

show abstract

“…The current study demonstrated that hirsute females displayed indications of hyperandrogenism more frequently than controls, which is caused by either an increase in blood testosterone levels or a hypersensitivity to it. By directly affecting the hair follicle and pilosebaceous unit (PSU), androgen excess causes hirsutism, FPHL, and acne (24) . Two pathways seem to be involved in how androgens help villus hair become terminal hair.…”

Section: Discussionmentioning

confidence: 99%

Estimation of Serum Level of Omentin-1 In Hirsute Female: A Single Center Study

Elbhoty¹,

Fayed²,

Ebrahim³

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Hirsutism in females is defined as the presence of an androgen-dependent pattern of profuse terminal hair. The specific effect of Omentin-1 on hair development is not yet established. Omentin-1, on the other hand, has the potential to stimulate hair growth by either causing vasodilation or activating phosphatidylinositol 3-kinase (PI3K).Objective: This study aimed to evaluate serum level of omentin-1 in hirsute females in comparison with normal non hirsute.Patients and methods: This study included 42 females with hirsutism (21 idiopathic, 21 with polycystic ovary syndrome (PCOS) and 42 healthy matched controls. The included patients were chosen randomly from the Laser Unit in Dermatology Department of Mansoura University Hospital's. All patients were subjected to history taking, dermatological and gynecological examination, diagnosis of hirsutism, diagnosis of PCO, hormonal profile, assessment of serum omentin level. Results: Hirsutism with PCO subgroup showed significantly lower dehydroepiandrosterone sulphate (DHEA-S), significantly higher testosterone (TT), fasting blood glucose (FBG), fasting insulin, HOMA-IR when compared to those with idiopathic hirsutism subgroup (p<0.001 for each). Higher omentin-1 level was significantly associated with idiopathic hirsutism when compared to hirsutism with PCO subgroups (mean= 309.7 versus 184.6, p<0.001). Detection of omentin-1 level could be used as reliable indicator in discrimination between idiopathic hirsutism and those with PCO subgroups (AUC=0.912) with high sensitivity (95.2%) and specificity (95.2%). Conclusion:In females with idiopathic hirsutism, serum omentin-1 is increased, and this rise may contribute to excessive hair growth.

show abstract

Managing the PCOS-Related Symptoms of Hirsutism, Acne, and Female Pattern Hair Loss

Cited by 3 publications

References 87 publications

Impact of Laser Therapy on the Quality of Life in Women Living With Polycystic Ovary Syndrome-Associated Hirsutism: An Observational Study

Impact of Laser Therapy on the Quality of Life in Women Living With Polycystic Ovary Syndrome-Associated Hirsutism: An Observational Study

Estimation of Serum Level of Omentin-1 In Hirsute Female: A Single Center Study

Contact Info

Product

Resources

About